Semax 10mg Nootropic Heptapeptide | Cognitive & Neuroprotective Research Peptide

Semax 10mg Nootropic Heptapeptide | Cognitive & Neuroprotective Research Peptide

Overview Semax is a synthetic heptapeptide originally developed as a research analogue of the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), engineered without the corticotropic activity of the parent hormone. The 10mg presentation is developed for advanced research into cognition, neuroprotection, and central nervous system signalling — positioning it among the most widely studied nootropic-class research peptides.

Mechanism of Interest Semax is recognised in the research literature for its influence on the brain's neurotrophic and monoaminergic systems. Studies have explored its role in modulating brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), dopaminergic and serotonergic signalling, and enkephalin-related pathways. Its compact heptapeptide structure and metabolic stability make it a refined research tool in models of cognitive performance, neuroplasticity, and neuroprotection.

Product Specifications

• Product Name: Semax 10mg
• Catalogue Reference: SEM10-024
• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
• Molecular Formula: C₃₉H₅₄N₁₀O₁₀S
• Molecular Weight: 813.95 g/mol
• Purity: ≥98% (HPLC verified)
• Presentation: Lyophilised solid
• Storage: -20°C

Research Applications Semax is utilised across neuroscience, cognitive research, and neurorestorative biology — particularly in studies investigating attention and memory models, BDNF and NGF expression, ischaemic and hypoxic brain injury models, stress adaptation, and neuroprotective signalling pathways. Its broad activity across neurotrophic and monoamine systems makes it a versatile tool in CNS-focused research.

Comparative Research Context Semax is frequently studied alongside Selank, P21, and other ACTH-derived research peptides in comparative nootropic and neuroprotective models — where its profile is differentiated by its emphasis on neurotrophic factor expression and dopaminergic modulation.

Quality & Handling Synthesised under controlled laboratory conditions and supplied as a lyophilised solid for maximum stability. Reconstitution with appropriate bacteriostatic solution is required prior to use in any research model. Every batch is subjected to rigorous quality control to ensure ≥98% purity, identity, and reproducibility.

Compliance Statement All Asclepius peptide products are supplied strictly for laboratory research purposes. They are not intended for human consumption, diagnosis, treatment, or therapeutic use. Enquiries relating to human application cannot be supported.

Order with Confidence Asclepius peptides are sourced, tested, and dispatched to a clinical standard — built for researchers and practitioners who refuse to compromise on integrity, purity, or precision.

For technical specifications, certificates of analysis, or research support, our team is available to assist.